Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5449161 | 0.84 | PTPN11 (0.46) | CA1CA2MAPTNPC1CYP3A4 | |
| SCHEMBL808434 | 0.74 | MPO (0.58) | CA1CA2MAPTNPC1CYP3A4 | |
| SCHEMBL14920105 | 0.71 | MAPT (0.47) | CA1CA2MAPTNPC1MEN1 | |
| SCHEMBL4189157 | 0.70 | MAPT (0.70) | CA1CA2MAPTALDH1A1PLAU | |
| SCHEMBL5693970 | 0.69 | CA1 (0.71) | CA1CA2MAPTNPC1ALDH1A1 | |
| SCHEMBL9648378 | 0.69 | MPO (0.56) | CA1CA2MAPTNPC1CYP3A4 | |
| SCHEMBL18951239 | 0.69 | CYP2A6 (0.55) | CA1CA2MAPTNPC1CYP3A4 | |
| SCHEMBL12571872 | 0.69 | OGG1 (0.66) | CA1CA2MAPTNPC1MEN1 | |
| SCHEMBL21241276 | 0.68 | PLAU (0.62) | CA1CA2MAPTNPC1CYP3A4 | |
| SCHEMBL1149678 | 0.68 | NPC1 (0.62) | MAPTNPC1MEN1KMT2AHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135485-A1 | Novel mch receptor antagonists | ELI LILLY AND COMPANY | 2007-06-14 | — | — | US | disclosed |
| EP-1723126-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005040157-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135485-A1 | Novel mch receptor antagonists | MCHR1, MCHR2, MC1R | CA1 4381/4885CA2 1917/4885MAPT 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.